Shares of Moderna rise 2.5% to $164 after the market.The breakthrough tag is granted by the U.S. Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44% compared with Keytruda alone.The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli and Shailesh Kuber)